Kinase inhibitors for the treatment of inflammatory and autoimmune disorders

被引：39

作者：

Bhagwat, Shripad S. ^{[1
]}

机构：

[1] Ambit Biosci, San Diego, CA 92121 USA

来源：

PURINERGIC SIGNALLING | 2009年 / 5卷 / 01期

关键词：

Kinase inhibitors; Anti-inflammatory agents; Autoimmune modulators; IKK2; inhibitors; Syk inhibitors; Lck inhibitors; JAK3; KAPPA-B KINASE; IKK-BETA INHIBITORS; POTENT; DISCOVERY; SYK; JAK3; LCK; SAR; DERIVATIVES; BMS-345541;

D O I：

10.1007/s11302-008-9117-z

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Drugs targeting inhibition of kinases for the treatment of inflammation and autoimmune disorders have become a major focus in the pharmaceutical and biotech industry. Multiple kinases from different pathways have been the targets of interest in this endeavor. This review describes some of the recent developments in the search for inhibitors of IKK2, Syk, Lck, and JAK3 kinases. It is anticipated that some of these compounds or newer inhibitors of these kinases will be approved for the treatment of rheumatoid arthritis, psoriasis, organ transplantation, and other autoimmune diseases.

引用

页码：107 / 115

页数：9

共 50 条

[31] Selective protein kinase Cθ (PKCθ) inhibitors for the treatment of autoimmune diseases
Curnock, Adam
Bolton, Clare
Chiu, Peter
Doyle, Elisabeth
Fraysse, Damien
Hesse, Matthias
Jones, Julie
Weber, Peter
Jimenez, Juan-Miguel
BIOCHEMICAL SOCIETY TRANSACTIONS, 2014, 42 : 1524 - 1528
[32] Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases
Tang, Su'an
Yu, Qinghong
Ding, Changhai
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (03) : 291 - 303
[33] P38 MAP kinase inhibitors for the treatment of inflammatory disorders: Scaffold diversity as a method for potency optimization
Hynes, John, Jr.
Wu, Hong
Dyckman, Alaric
Lin, Shuqun
Wrobleski, Stephen
Gillooly, Kathleen
Kanner, Steven
Lonia, Herinder
Loo, Derek
Mcintyre, Kim
Pitt, Sidney
Shen, Ding Ren
Shuster, David J.
Yang, Xiaoxia
Zhang, Rosemary
Behnia, Kamelia
Zhang, Hongjian
Marathe, Punit
Doweyko, Arthur
Sack, John S.
Kish, Kevin
Kiefer, Susan E.
Newitt, John A.
Barrish, Joel
Dodd, John
Schieven, Gary L.
Leftheris, Katerina
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
[34] Narrow Spectrum Kinase Inhibitors Demonstrate Promise for the Treatment of Dry Eye Disease and Other Ocular Inflammatory Disorders
Hagan, Suzanne
Fyfe, Matthew C. T.
Ofori-Frimpong, Boatemaa
Oliver, Katherine
Foster, Martyn R.
Sirohi, Sameer
Solanke, Yemisi
Doughty, Michael
Rowley, Adele
Taylor, Mike
Webber, Steve
Walshe, Claire A.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (03) : 1443 - 1453
[35] Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors
Zheng, Jiamin
Wu, Jun
Ding, Xiao
Shen, Hong C.
Zou, Ge
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 38
[36] Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
Roskoski, Robert, Jr.
PHARMACOLOGICAL RESEARCH, 2016, 111 : 784 - 803
[37] Development of specific Kinase-Inhibitors for the Treatment of inflammatory Diseases
Neubauer, G.
ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2012, 62 (12): : 690 - 690
[38] The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment
Kim, Jin-Woo
Kim, Su-Young
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (21)
[39] Targeting IκB kinase for the treatment of inflammatory and other disorders
Burke, JR
CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2003, 6 (05) : 720 - 728
[40] Protein Kinase C-theta Inhibitors: A Novel Therapy for Inflammatory Disorders
Chand, Sukhvir
Mehta, Nisha
Bahia, Malkeet Singh
Dixit, Anshuman
Silakari, Om
CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (30) : 4725 - 4746

← 1 2 3 4 5 →